Welcome to the Senedd’s new website. If you have any difficulty using this site please get in touch.
Statement in response to the Welsh Government’s announcement on Access to Cystic Fibrosis Triple Therapy
Published 23/07/2020   |   Last Updated 01/12/2020   |   Reading Time minutes
The Chair of the Senedd’s Petitions Committee has issued a statement in response to the announcement by the Health and Social Services Minister, Vaughan Gething MS, on Access to Cystic Fibrosis Triple Therapy which was issued yesterday, Wednesday 22 July.
The Committee Chair, Janet Finch-Saunders MS, says:
“We welcome the news that people with cystic fibrosis in Wales will be able to access the new triple therapy combination drug Kaftrio. This will ensure improved treatment with the most appropriate medicine, which will improve many cystic fibrosis patient’s health and quality of life.
“We are pleased that the Cystic Fibrosis Trust acknowledge the vital work of the Committee in its consideration of a petition calling on access to the cystic fibrosis medicine, Orkambi, which became available in Wales in November 2019. The negotiations between NHS Wales and Vertex Pharmaceuticals regarding Orkambi laid the foundations for progress in relation to the triple therapy combination.”
A petition was presented to the Senedd calling on the National Assembly for Wales (since changed to Senedd Cymru and Welsh Parliament) to call for a resolution to ongoing negotiations between NHS Wales, the All Wales Medicines Strategy Group, the Welsh Health and Specialised Services Committee and Vertex Pharmaceuticals regarding access to the cystic fibrosis medicine, Orkambi, as a matter of the utmost urgency. The petition gathered 5,717 signatures and was considered by the Senedd’s Petitions Committee.